United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Viracta Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
| ROE | -128.57% | -2.81% | -2.89% | -2.97% | -3.07% | -3.17% |
|---|---|---|---|---|---|---|
| ROA | -66.88% | -0.87% | -0.87% | -0.87% | -0.87% | -0.87% |
| Total Assets | $56,692.00K | $56,692.00K | $56,692.00K | $56,692.00K | $56,692.00K | $56,692.00K |
| Net Income | -$51,058.00K | -$493.15K | -$493.32K | -$493.52K | -$493.75K | -$494.01K |